Merck & Co., Inc. $MRK Stock: Valley National Advisers Inc. Lowers Holdings

Valley National Advisers Inc. trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 55.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,245 shares of the company’s stock after selling 24,712 shares during the period. Valley National Advisers Inc.’s holdings in Merck & Co., Inc. were worth $2,942,000 as of its most recent filing with the Securities and Exchange Commission.

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares during the last quarter. State Street Corp raised its holdings in shares of Merck & Co., Inc. by 0.9% in the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after purchasing an additional 1,087,583 shares during the period. Wellington Management Group LLP raised its holdings in shares of Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after purchasing an additional 1,934,312 shares during the period. Bank of America Corp DE lifted its stake in Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after purchasing an additional 2,919,780 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Merck & Co., Inc. by 23.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock valued at $1,858,938,000 after purchasing an additional 2,969,856 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Get Merck & Co., Inc. alerts:

Merck & Co., Inc. Price Performance

Shares of MRK opened at $145.25 on Friday. The company’s 50-day moving average is $146.98 and its 200-day moving average is $130.17. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The firm has a market capitalization of $358.35 billion, a PE ratio of 116.20, a PEG ratio of 6.74 and a beta of 0.21. Merck & Co., Inc. has a fifty-two week low of $82.01 and a fifty-two week high of $156.92.

3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the previous year, the firm posted $2.13 EPS. Merck & Co., Inc.’s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts forecast that Merck & Co., Inc. will post 2.64 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were paid a $0.85 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.’s payout ratio is 272.00%.

Analyst Upgrades and Downgrades

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning

A number of equities analysts recently commented on MRK shares. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target for the company in a report on Wednesday, August 12th. Weiss Ratings upgraded Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 25th. UBS Group raised their price objective on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Jefferies Financial Group raised their price objective on Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Finally, Berenberg Bank lifted their target price on Merck & Co., Inc. from $127.00 to $137.00 and gave the stock a “hold” rating in a research note on Friday, September 11th. Seventeen equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average target price of $151.92.

Check Out Our Latest Analysis on MRK

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the transaction, the executive vice president directly owned 46,613 shares of the company’s stock, valued at $6,106,303. This represents a 24.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP David Maraldo sold 18,706 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares in the company, valued at $2,344,248.64. The trade was a 50.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is currently owned by company insiders.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

Positive Sentiment: Merck and Moderna reported positive Phase 3 INTerpath-001 results for the personalized melanoma vaccine, intismeran, combined with Keytruda. The treatment reduced the risk of recurrence or death by 42% and also improved distant metastasis-free survival, supporting the long-term potential of the partnership’s oncology pipeline. Doctors call Moderna and Merck cancer vaccine data a major advancement
Positive Sentiment: The European Commission approved Keytruda plus Padcev as a perioperative treatment for resectable muscle-invasive bladder cancer, regardless of patients’ cisplatin eligibility. The broader label expands the addressable market and represents the EU’s first approval of a PD-1 inhibitor combined with an antibody-drug conjugate in this setting. Merck wins EU approval for Keytruda plus Padcev
Neutral Sentiment: Despite strong clinical results, the vaccine announcement triggered a “sell-the-news” reaction. The data largely met elevated Wall Street expectations after an earlier leak, limiting the immediate upside for MRK even though oncologists viewed the results as an important treatment advance. Merck and Moderna shares fall on cancer vaccine results
Negative Sentiment: Investors remain concerned about valuation and Merck’s future revenue concentration in Keytruda ahead of its patent cliff. Analysts have also characterized the recent rally as leaving limited margin of safety, increasing the risk of profit-taking when news is merely in line with expectations. Merck rally leaves little margin of safety
Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate to $2.63 from $2.73 and its FY2027 estimate to $9.38 from $9.47. Separate previews also anticipate a year-over-year decline in quarterly earnings, adding near-term pressure to the shares. Merck earnings preview

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Merck & Co., Inc. wasn’t on the list.

While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report